Ultraviolet-B Irradiation Decreases IFN-gamma and Increases IL-4 Expression in Psoriatic Lesional Skin in Situ and in Cultured Dermal T Cells Derived from These Lesions
Overview
Affiliations
Type 1 cytokine producing T cells play an important role in the pathogenesis of psoriasis. Ultraviolet-B (UVB) irradiation is effective in the treatment of this disease. In normal skin, UVB causes a change in dermal microenvironment, leading to a decrease of IFN-gamma expressing type 1 T cells and a concurrent increase of IL-4 expressing type 2 T cells. The aim of this study was to show whether UVB irradiation causes a like-wise shift of type 1 and type 2 responses in psoriatic skin. For this purpose, biopsies were obtained from the lesional skin of psoriatic patients before, 2 days and 14 days after a single exposure to 4 MED UVB. Sections from these biopsies were immunostained (CD3, IFN-gamma and IL-4) or RNA was extracted and analyzed for the expressions of IFN-gamma and IL-4 by PCR. In addition, primary cultures of T cells from dermal cell suspensions were stained intracellularly for IFN-gamma and IL-4 expression and CD4+ and CD8+ T subsets were analyzed by flow cytometry. IFN-gamma was abundantly expressed in situ before irradiation and decreased in all patients after UVB irradiation, whereas IL-4 expression was variably expressed before irradiation and increased in different degrees after irradiation. Cytokine mRNA expressions determined by PCR showed a clear decrease of IFN-gamma and increase of IL-4 following UVB irradiation. Both CD4+ and CD8+ dermal T cells were found to produce less IFN-gamma and more IL-4 following UVB irradiation as determined by flow cytometry. Decrease in IFN-gamma expression and increase in IL-4 expression of dermal T cells in psoriatic lesions after UVB irradiation may lead to decrease in local immunoreactivity. These changes could be part of the therapeutic effects of UVB on psoriasis.
Jun-Ting T, Ying T, Xiang N, Dong-Jie S, Li H Mediators Inflamm. 2025; 2025:7967853.
PMID: 39949921 PMC: 11824299. DOI: 10.1155/mi/7967853.
Vacharanukrauh P, Meephansan J, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, Serirat O Psoriasis (Auckl). 2021; 11:133-149.
PMID: 34858799 PMC: 8631988. DOI: 10.2147/PTT.S335913.
Zheng X, Wang Q, Luo Y, Lu W, Jin L, Chen M Clin Cosmet Investig Dermatol. 2021; 14:459-465.
PMID: 34007198 PMC: 8121268. DOI: 10.2147/CCID.S312556.
Elghandour T, Youssef S, Aly D, Abd Elhameed M, Abdel Moneim M Dermatol Res Pract. 2014; 2013:618269.
PMID: 24489536 PMC: 3893776. DOI: 10.1155/2013/618269.
Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients.
Elango T, Dayalan H, Gnanaraj P, Malligarjunan H, Subramanian S Clin Exp Med. 2013; 14(4):431-7.
PMID: 23949337 DOI: 10.1007/s10238-013-0252-7.